Cissus for Weight and Metabolic Outcomes: The Trials

This is the strange part of the Cissus file. The plant's traditional claim is fracture healing, where the evidence is old, weak and positive. The plant's commercial claim is weight loss — and there the evidence is modern, randomised, placebo-controlled, and compromised in a different way. There really are double-blind trials reporting weight, body-fat, lipid and glucose improvements. They are also small, short, clustered around a handful of investigators and one proprietary extract, and — the point that matters most — several of them administered a multi-ingredient product, which means a positive result cannot be credited to Cissus quadrangularis without checking what was in the capsule.

That last problem is not a technicality. It is the difference between "this plant reduces body fat" and "a formula containing this plant plus another plant reduces body fat", and the supplement market prints the first while citing the second.

Table of Contents

  1. What Is Claimed
  2. The Trials, Read as Designs
  3. Check What Was Actually Administered
  4. Investigator Clustering and Sponsorship
  5. Proposed Mechanisms
  6. The Cortisol-Blocker Story
  7. Glucose and Lipids: Benefit and Hazard in One Property
  8. Eight Weeks and What It Cannot Tell You
  9. What a Trial That Settled This Would Need
  10. Against Interventions That Do Have Evidence
  11. Evidence Ledger
  12. Numbers This Page Refuses to Give
  13. Key Research Papers
  14. Connections

What Is Claimed

The marketing bundle usually contains five separate assertions:

  1. Body weight and body fat fall on a Cissus extract, with or without diet change.
  2. Metabolic-syndrome markers improve — total and LDL cholesterol, triglycerides, fasting glucose.
  3. Appetite is reduced, usually attributed to serotonergic or hormonal effects.
  4. Fat absorption is reduced by pancreatic lipase inhibition.
  5. Cortisol is "blocked", preventing stress-related abdominal fat gain.

Claims 1 and 2 have randomised human trials behind them, and this page takes them seriously. Claims 3 and 4 rest on enzyme assays and animal work. Claim 5 has essentially nothing and is discussed separately because it is the most confidently asserted of the five.

The Trials, Read as Designs

Evidence tier: randomised, placebo-controlled, small, short, clustered, industry-supplied material, and in several cases multi-ingredient.

The core body of work comes from a group publishing out of Cameroon in Lipids in Health and Disease in the mid-to-late 2000s, associated with J. E. Oben and colleagues, using proprietary standardised Cissus extract material.

  1. Oben and colleagues, 2006 — The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Randomised and placebo-controlled in overweight and obese adults, with reported reductions in body weight and body fat and improvements in lipid and glucose measures over roughly eight weeks. Note the word "formulation" in the title. Before attributing the result to the plant, read the methods and establish exactly what the capsule contained — this page does not assume it was a single ingredient.
  2. Oben and colleagues, 2007 — a study contrasting a Cissus-alone extract (identified as CQR-300) with a multi-ingredient Cissus formulation in obesity and obesity-induced oxidative stress. This design is the most useful one in the whole file, because it is the only place where the single-plant material and the formula are examined side by side. If you want to know what Cissus does on its own, this is the paper to read, and it should be read rather than summarised from a label.
  3. Oben and colleagues, 2008 — The use of a Cissus quadrangularis / Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Three arms: Cissus alone, Cissus plus Irvingia gabonensis, and placebo, over roughly ten weeks, with the combination arm reported as the largest effect. The combination is the headline result, and Irvingia gabonensis is a separate plant with its own weight-loss literature from the same research group. A larger effect in a two-plant arm is evidence about two plants.
  4. Smaller pilot and open-label studies using various extracts, sometimes alongside dietary advice, reporting modest weight and lipid changes. Several lacked blinding. These add volume rather than strength.
  5. Sawangjit and colleagues, 2017 — systematic review and meta-analysis of randomised trials of Cissus quadrangularis in clinical use, in Phytotherapy Research. It pools the randomised evidence across indications and concludes the base is limited in both quantity and quality. This is the appropriate reference for anyone who wants one citation rather than five.

Check What Was Actually Administered

This is the decisive methodological point on the page, and it generalises well beyond Cissus.

When a trial administers a formula and reports a benefit, the benefit belongs to the formula. Crediting it to one named constituent requires either a single-ingredient arm, or a design that isolates the component. In the Cissus weight-loss literature:

What this page therefore does not claim: that Cissus quadrangularis alone has been shown to produce weight loss. What it claims is that randomised trials of Cissus-containing materials have reported weight and metabolic improvements, that at least one design examined the plant alone, and that anyone relying on this literature must read the methods rather than the abstract.

Investigator Clustering and Sponsorship

Reporting funding and authorship relationships is not an accusation; it is part of describing the evidence, and it is disclosed in the papers themselves.

Proposed Mechanisms

Four mechanisms are offered. All are hypotheses about why an effect might exist rather than evidence that it does.

The Cortisol-Blocker Story

Cissus is sold across the fitness market as a "cortisol blocker" that prevents stress-driven abdominal fat gain. This deserves its own section because it is asserted with more confidence than anything else on the label and supported by less.

What exists: the plant contains phytosterols and, by the industry's own standardisation, a fraction marketed as "ketosterones", and 3-ketosteroids are structurally in the same broad chemical territory as steroid hormones. What does not exist: any adequate human study showing that oral Cissus lowers cortisol, and any study linking such a change to fat distribution. Structural resemblance is not pharmacology.

Two further problems sit underneath the claim. First, the ketosterone assay is not standardised between laboratories, so the marketed fraction is not a defined quantity. Second, "blocking cortisol" is not obviously desirable even if it were achievable — cortisol is required for glucose regulation, blood pressure and the response to physical stress, and an agent that genuinely suppressed it would carry the safety profile of a corticosteroid antagonist, not of a fat burner. A mechanism that would be dangerous if true, and is asserted without evidence, is worth naming as marketing rather than pharmacology.

Glucose and Lipids: Benefit and Hazard in One Property

Several trials and animal studies report lower fasting glucose with Cissus. Taken as a benefit claim this is modest and unconfirmed. Taken as a safety observation it is the most practically important finding on this page — and it is the same property described twice.

If the glucose-lowering effect is real, it is additive with the drugs people already take for that purpose: metformin, sulfonylureas such as glipizide, glyburide and glimepiride, meglitinides, and insulin. Someone whose medication was titrated before they started the supplement can drift into more frequent hypoglycaemia, and the symptoms — shakiness, sweating, confusion — are easily misread as a side effect of the herb rather than an interaction with the prescription. Anyone in that position should tell the prescriber, monitor more closely for the first weeks, and know their hypoglycaemia symptoms. This is expanded in Cissus: Dose, Formulations and Safety.

The reported lipid changes carry a milder version of the same logic: worth monitoring in someone on a statin or an antihypertensive, not because an interaction is documented, but because an unmeasured variable has been added to a titrated regimen. See Lipid Panel and Hemoglobin A1C.

Eight Weeks and What It Cannot Tell You

The trials ran roughly eight to ten weeks. Three things follow, and they are not minor.

  1. Nothing about weight maintenance. Almost any intervention produces weight loss over eight weeks; the entire difficulty of obesity treatment is the twelve to twenty-four month horizon, where most losses are regained. A short trial cannot address the actual clinical question. See Obesity.
  2. Nothing about safety over the period of real use. People take supplements for years. Eight weeks cannot detect a slowly accumulating harm, and with a plant carrying meaningful oxalate that is not an abstract concern — see Kidney Stones.
  3. Nothing about uncommon adverse events. A hundred participants split across arms cannot detect a harm occurring in one user in a few hundred.

What a Trial That Settled This Would Need

Naming the study that would resolve the question is more useful than hedging, and obesity pharmacotherapy has a mature, well-specified trial methodology to borrow from.

  1. A single-ingredient, assayed intervention with a documented certificate of analysis, so the trial tests the plant and not a mixture.
  2. Randomised, double-blind, placebo-controlled, with a matched placebo and allocation concealment.
  3. Twelve months minimum, which is the standard duration for a weight-loss agent, with a maintenance phase.
  4. Percentage body-weight change as the primary endpoint, plus the proportion of participants achieving five and ten percent loss — the thresholds regulators and clinicians use.
  5. Body composition by DXA or equivalent, not bioimpedance, so a fat-versus-lean claim can be made honestly.
  6. Standardised background diet and activity, or at minimum measured and reported, since unmeasured lifestyle change is the commonest confounder in supplement trials.
  7. Prespecified metabolic secondary endpoints: fasting glucose, HbA1c, a full lipid panel, blood pressure, waist circumference.
  8. Adequate power for a modest effect, meaning several hundred participants across multiple independent sites.
  9. Pre-registration, intention-to-treat analysis and an independent statistician, which given the funding history of this literature is a requirement rather than a nicety.

None of this is beyond a botanical. It is how orlistat, and later the GLP-1 agonists, were assessed. Twenty years after the first positive Cissus trial, no study of this shape has been published.

Against Interventions That Do Have Evidence

The point of naming comparators is to show that the question is answerable, not to sell an alternative.

Evidence Ledger

  1. Best supported: that randomised placebo-controlled trials of Cissus-containing materials have reported short-term weight, body-fat, lipid and fasting-glucose improvements. Tier: modern randomised human evidence, small, short, clustered, and in several cases multi-ingredient.
  2. Materially weaker than it looks: attribution of those results to Cissus quadrangularis alone. Tier: partly confounded — at least one design isolates the single plant, and it is not the design most often cited.
  3. Mechanistic, not clinical: lipase, amylase and glucosidase inhibition. Tier: in vitro, with no human pharmacokinetics to bridge the gap.
  4. Asserted without evidence: cortisol blocking. Tier: marketing — and a mechanism that would carry corticosteroid-antagonist risks if it were real.
  5. Absent: anything about weight maintenance beyond ten weeks, and anything about safety over years of use.
  6. The most robust finding on this page is a safety observation, not a benefit: the reported glucose-lowering effect, which matters most to people taking diabetes medication.

Numbers This Page Refuses to Give

Key Research Papers

Every citation is a PubMed search built from author names and distinctive title words rather than a numeric identifier, so a link cannot silently resolve to the wrong paper. Confirm the record before relying on it. Citations involving a second plant or a formulation are labelled as such at the citation.

  1. Systematic review and meta-analysis — the appropriate single citation. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomised controlled trials. Phytotherapy Research, 2017. Find on PubMed.
  2. The 2006 trial — note "formulation" in the title. Oben JE and colleagues. The use of a Cissus quadrangularis formulation in the management of weight loss and metabolic syndrome. Lipids in Health and Disease, 2006. Read the methods for the composition of the tested material before attributing the result. Find on PubMed.
  3. Single plant versus formulation, side by side. Oben JE and colleagues on Cissus quadrangularis (CQR-300) and a Cissus formulation in obesity and obesity-induced oxidative stress, Lipids in Health and Disease, around 2007. The most useful design in the file for isolating what the plant alone does. Find on PubMed.
  4. Two-plant combination — the headline arm is not Cissus alone. Oben JE, Ngondi JL and colleagues. The use of a Cissus quadrangularis / Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study. Lipids in Health and Disease, 2008. Find on PubMed.
  5. Different plant — cited to show where part of the combination effect may live. Work by Oben, Ngondi and colleagues on Irvingia gabonensis seed extract and adipogenesis, including effects on PPAR-gamma, leptin and adiponectin expression, in Lipids in Health and Disease. This is African mango, not Cissus. Find on PubMed.
  6. Industry-adjacent review. Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytotherapy Research, 2013. Read the competing-interests statement alongside the conclusions. Find on PubMed.
  7. Enzyme-inhibition mechanism — in vitro only. Reports of pancreatic lipase, alpha-amylase and alpha-glucosidase inhibition by Cissus quadrangularis extracts. Confirm journals and years from the records; these are assays, not doses. Search PubMed.
  8. Antihyperglycaemic and antihyperlipidaemic animal work. Rodent studies reporting lower glucose and improved lipid profiles with Cissus quadrangularis extracts — the preclinical basis of the safety point in this page rather than of a treatment claim. Search PubMed.
  9. Safety assessment of a standardised extract. Subchronic toxicity and genotoxicity evaluation of a standardised Cissus quadrangularis extract, published in the toxicology literature around 2011. Metadata should be confirmed from the record; the study is industry-associated. Search PubMed.
  10. How weight-loss agents are actually assessed. Regulatory-standard endpoints in obesity pharmacotherapy trials — twelve-month duration, percentage weight change, five and ten percent responder thresholds. The bar a supplement claim is implicitly measuring itself against. Search PubMed.
  11. Why short trials mislead. Long-term weight-regain literature after successful short-term loss. Search PubMed.

Live PubMed Searches

  1. Cissus quadrangularis, obesity, randomised trials
  2. Cissus quadrangularis and metabolic syndrome
  3. Cissus quadrangularis and blood glucose
  4. Cissus quadrangularis and cortisol — see how little returns.
  5. Irvingia gabonensis and weight loss — the other plant in the combination.

External Resources

Connections

Back to Table of Contents